Loading page
Loading page
Loading substance route
2C-E exhibits an unusually steep dose-response curve. Small dose increments produce disproportionately large increases in intensity. Individual sensitivity varies considerably.
Effects vary widely by individual, dose, and context.
The head space of 2C-E is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
The visual geometry of 2C-E can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B, or 2C-I. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, sharp in their edges, and equally rounded and angular in their corners. They give off a contradictory natural and synthetic feel that at higher dosages are significantly more likely to result in states of Level 7B visual geometry over Level 7A.
2C-E produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics, particularly in comparison to other substances within the phenethylamine family.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Like most psychedelics, 2C-E is not considered habit-forming. Anecdotal evidence suggests the desire to use it may actually decrease with use due to its powerfully introspective and mentally therapeutic effects.
2C-E does not appear to be physically addictive. No withdrawal symptoms have been documented.
The LD50 in humans is not known. At least two deaths have been attributed to 2C-E overdose, though the exact toxic dose remains unclear. The toxicity and long-term health effects have not been studied in any scientific context.
Adverse psychological reactions including delirium, agitation, paranoia, and hallucinations have been reported, particularly at higher doses. User reports describe experiencing auditory hallucinations and paranoid ideation at doses around 25mg. Risk of psychotic symptoms increases significantly when combined with cannabis, dissociatives, stimulants, or lithium.
Seizures are rarely observed but are believed to be a risk in predisposed individuals, especially under physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
2C-E was first synthesized by Alexander Shulgin in 1977. His findings were documented in detail in the 1991 book PiHKAL (Phenethylamines I Have Known and Loved), co-authored with Ann Shulgin. This influential work contained synthesis instructions, bioassays, dosages, and commentary for over 200…
In Queensland, added to the 'Dangerous Drugs' list under the Drugs Misuse Amendment Act 2008, making production, supply, and possession illegal.
Possession, production, and sale prohibited under Portaria SVS/MS nº 344 since February 18, 2014.
Controlled since October 2015. Sale, purchase, import, export, and manufacture are illegal.
Possession, production, and sale prohibited. Banned in December 2014 under a government regulation controlling over 100 psychoactive substances.
Added to Israel's controlled substances list in December 2007, making purchase, sale, and possession illegal.
Classified as a Schedule I controlled substance under national drug legislation.
Classified as a controlled substance within the IV-P psychotropic group under Polish drug legislation.
Classified as dangerous to health under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor) since October 1, 2004, via regulation SFS 2004:696. Sale and possession are illegal.
Classified as a controlled drug. Possession, production, supply, and import are prohibited.
Federally controlled under the Food and Drug Administration Safety and Innovation Act of 2012 as of July 9, 2012. Possession, distribution, and manufacture are illegal without DEA license. Additionally scheduled at state level in Alabama, Louisiana, Minnesota, Oklahoma, Pennsylvania, Vermont, and Virginia.
Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG). The accompanying NPSV regulation explicitly bans all substituted phenethylamines under Schedule II.
Classified under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016, as a derivative of 2,5-dimethoxyphenethylamine.
Added to the list of Schedule B controlled substances as of April 8, 2007.
Listed under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) as of December 13, 2014. Manufacturing, possession, import, export, purchase, sale, and dispensing without license are prohibited.
Controlled under the Pharmaceutical Affairs Law, prohibiting possession and sale.
Controlled under the catch-all Analogues section in Schedule 3 / Class C of the Misuse of Drugs Act, alongside other phenethylamine derivatives.
Possession of quantities not exceeding a ten-day personal supply is decriminalized. Production and distribution remain criminal offenses.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971 following the 2002 amendment, which introduced a phenethylamine catch-all clause covering 2C-E and related compounds. Production, supply, and possession are illegal.
18 sources cited
